Hims & Hers Health (NYSE:HIMS) Stock Price Up 5.7% – Time to Buy?

Hims & Hers Health, Inc. (NYSE:HIMS) shares rose 5.7% on Tuesday . The stock traded as high as $31.39 and last traded at $32.25. Approximately 977,399 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 9,715,154 shares. The stock had previously closed at $30.51.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on HIMS shares. Needham & Company LLC boosted their price objective on shares of Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, January 6th. TD Cowen reaffirmed a “buy” rating and set a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Bank of America cut shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their price target for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Finally, BTIG Research began coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 target price for the company. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and a consensus price target of $25.13.

Hims & Hers Health Price Performance

The stock has a market cap of $6.95 billion, a PE ratio of 72.29 and a beta of 1.31. The company’s fifty day moving average is $28.77 and its 200-day moving average is $22.39.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.26. The business had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company’s revenue for the quarter was up 77.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.04) EPS. Analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Transactions at Hims & Hers Health

In related news, insider Michael Chi sold 2,054 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $33.56, for a total transaction of $68,932.24. Following the completion of the transaction, the insider now owns 184,947 shares in the company, valued at $6,206,821.32. This represents a 1.10 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Andrew Dudum sold 27,098 shares of the company’s stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $30.08, for a total value of $815,107.84. Following the completion of the sale, the chief executive officer now owns 27,918 shares of the company’s stock, valued at $839,773.44. This trade represents a 49.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,256,067 shares of company stock valued at $34,459,485 in the last 90 days. 17.71% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of HIMS. Crewe Advisors LLC purchased a new stake in shares of Hims & Hers Health in the 4th quarter valued at approximately $28,000. Raleigh Capital Management Inc. increased its position in shares of Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Hims & Hers Health by 2,173.7% in the 4th quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock valued at $54,000 after acquiring an additional 2,152 shares during the period. Quest Partners LLC increased its holdings in Hims & Hers Health by 22.6% in the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after purchasing an additional 807 shares during the last quarter. Finally, CWM LLC raised its position in Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.